Late effects of childhood cancer therapy
- PMID: 12720209
- DOI: 10.1053/jpdn.2003.13
Late effects of childhood cancer therapy
Abstract
One in every 900 young adults is a survivor of childhood cancer. Survivors may experience a wide variety of late effects stemming from the treatment they received. It is estimated that a significant portion of adult survivors of childhood cancer are not followed regularly in a center familiar with the late effects of their specific therapy. Therefore it is important for health care professionals in any setting to have an understanding of these possible late effects and encourage the survivor to seek appropriate follow-up. This article will provide a general overview of the potential late effects of childhood cancer therapy.
Copyright 2003, Elsevier Inc. All rights reserved.
Similar articles
-
Treatment strategies in childhood cancer.J Pediatr Nurs. 2003 Apr;18(2):103-12. doi: 10.1053/jpdn.2003.10. J Pediatr Nurs. 2003. PMID: 12720207 Review.
-
Development of risk-based guidelines for pediatric cancer survivors: the Children's Oncology Group Long-Term Follow-Up Guidelines from the Children's Oncology Group Late Effects Committee and Nursing Discipline.J Clin Oncol. 2004 Dec 15;22(24):4979-90. doi: 10.1200/JCO.2004.11.032. Epub 2004 Dec 2. J Clin Oncol. 2004. PMID: 15576413
-
Grading of late effects in young adult survivors of childhood cancer followed in an ambulatory adult setting.Cancer. 2000 Apr 1;88(7):1687-95. Cancer. 2000. PMID: 10738228
-
Survivors of childhood cancer: coming of age.Hematol Oncol Clin North Am. 2008 Apr;22(2):211-31, v-vi. doi: 10.1016/j.hoc.2008.01.011. Hematol Oncol Clin North Am. 2008. PMID: 18395146
-
Bone mineral density deficits in survivors of childhood cancer: long-term follow-up guidelines and review of the literature.Pediatrics. 2008 Mar;121(3):e705-13. doi: 10.1542/peds.2007-1396. Pediatrics. 2008. PMID: 18310191 Review.
Cited by
-
Urinary TIMP-2*IGFBP-7 to diagnose acute kidney injury in children receiving cisplatin.Pediatr Nephrol. 2024 Jan;39(1):269-282. doi: 10.1007/s00467-023-06007-8. Epub 2023 Jun 26. Pediatr Nephrol. 2024. PMID: 37365422
-
Design and Methods of the Pan-Canadian Applying Biomarkers to Minimize Long-Term Effects of Childhood/Adolescent Cancer Treatment (ABLE) Nephrotoxicity Study: A Prospective Observational Cohort Study.Can J Kidney Health Dis. 2017 Feb 16;4:2054358117690338. doi: 10.1177/2054358117690338. eCollection 2017. Can J Kidney Health Dis. 2017. PMID: 28270931 Free PMC article.
-
Modernizing Clinical Trial Eligibility: Recommendations of the American Society of Clinical Oncology-Friends of Cancer Research Minimum Age Working Group.J Clin Oncol. 2017 Nov 20;35(33):3781-3787. doi: 10.1200/JCO.2017.74.4144. Epub 2017 Oct 2. J Clin Oncol. 2017. PMID: 28968169 Free PMC article.
-
Safety of Complementary and Alternative Medicine (CAM) treatment among children and young adults who suffer from adverse effects of conventional cancer treatment: A systematic review.Integr Cancer Ther. 2022 Jan-Dec;21:15347354221105563. doi: 10.1177/15347354221105563. Integr Cancer Ther. 2022. PMID: 35726681 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources